|
Post by babaoriley on Oct 17, 2014 11:12:49 GMT -5
Sorry. I was trying to make a funny. Given both the pharmakinetic advantage of Afrezza and the obvious head start Mannkind has in development, certification and partnership, whether Dance exists or not really won't impact Afrezza sales one way or the other. But the inferiority of Dance vis-a-vis Mannkind didn't stop the naysayers from bashing Mannkind when Dance entered stage right. My post was tounge in cheek in suggesting that Dance's exit stage left will also be tauted by those same naysayers that Dance's inability to survive is proof that Mannkind cannot survive. It is sort of like the kid who said he didn't like camp because the food was so bad you couldn't eat it, and besides there wasn't enough food to have seconds. My apologizes if the humor was lost in translation. Well, Rocky, your humor was not lost on everyone! LOL! Of course, we have similar (fairly warped) senses of humor.
|
|
|
Post by jpg on Oct 17, 2014 12:27:03 GMT -5
Certainly no apologizes necessary. I just don't have any humour! And I get tired of hearing the same old empty (to me anyway) arguments from shorts. And the last few weeks have been painful... JPG Last few MONTHS have been painful!!! I watched the price performance June 30th after FDA approval and didn't like it, but didn't have the balls to sell anything...I'll be kicking myself about that one for the rest of my life. Also...5:20 AM EST time and the price is at $6.15 on light volume (2,100). I wonder what's going on. Anyone have an educated guess? I had some Illumina that crashed and went back up very very impressively. When it crashed (I had made real $ before that) and wiped out all my real profits (and some) I felt like you describe now for MNKD. I barely remember having felt bad but only wish I had bought a lot more Illumina as it went up almost 10x from the low in question. I suspect many will also have the same type of memory in a year or 2. My cost basis is low enough that I am still way above water (even at the recent lows) but still the experience is no fun. I did not once consider selling though. Biotech is volatile and catching the perfect or near perfect entry and exit points is impossible (of me at least). JPG
|
|
|
Post by cybergym66 on Oct 17, 2014 13:20:42 GMT -5
Last few MONTHS have been painful!!! I watched the price performance June 30th after FDA approval and didn't like it, but didn't have the balls to sell anything...I'll be kicking myself about that one for the rest of my life. Also...5:20 AM EST time and the price is at $6.15 on light volume (2,100). I wonder what's going on. Anyone have an educated guess? I had some Illumina that crashed and went back up very very impressively. When it crashed (I had made real $ before that) and wiped out all my real profits (and some) I felt like you describe now for MNKD. I barely remember having felt bad but only wish I had bought a lot more Illumina as it went up almost 10x from the low in question. I suspect many will also have the same type of memory in a year or 2. My cost basis is low enough that I am still way above water (even at the recent lows) but still the experience is no fun. I did not once consider selling though. Biotech is volatile and catching the perfect or near perfect entry and exit points is impossible (of me at least). JPG I'm sticking to my theory that this is a slow grind up. I have options (Jan '16s) so I'd love the price to spike but in the very least I need a steady rise. This isn't a 10X stock, but could be in the $30 range sometime in 2017. Of course this is subject to change as SNY & MNKD start selling Afrezza and hoping MNKD gets some deals for Technosphere.
|
|
|
Post by obamayoumama on Oct 17, 2014 22:13:21 GMT -5
I believe that one of the reason MNKD had a good week was the fact that DNCE pulled their IPO. The shorts were probably going to use the DNCE IPO to spread fear into MNKD shareholders and be able to close out their short positions in the 2-3 dollar range. Adam Fraudstein has been hyping DNCE for the last several months. I would not be surprised that the shorts started getting the DNCE info on Tuesday and then on Wednesday had to begin to close out some of their positions. Since there isn't a lot of selling by shareholders, ie. no DNCE IPO, they weren't planning on being trapped. Ouch!
|
|